INSERM Tenured Researcher in the field of Cardiovascular Research, currently focusing on therapeutic angiogenesis with polymer-based targeted growth factor delivery.
PhD in Tumor Biology (Pr Yihai Cao, Karolinska Institutet, Sweden), and expertise in Adipose tissue angiogenesis. Postdoc at UCLA (Pr Lily Wu) in molecular imaging and tumor lymphangiogenesis field.
Member of European Vascular Biology Organisation, French society for Cardiovascular Research, French society for Angiogenesis Research.
Associate Professor of Anesthesiology at University of Rochester Medical Center. PhD in Biochemistry from Cambridge University (UK) and post-doctoral training at the University of Alabama at Birmingham. Research program in mitochondria, cardiac ischemia, and cardioprotective therapies.
2002 Radiology Staff at the Erasmus University Medical Center (EMC) of Rotterdam, NL
2005 PhD in Cardiac Imaging at the EMC, Rotterdam, NL
2006-2011 Head of Cardiac Imaging at the Academic Hospital, Parma, IT
2011-2015 Head of Cardiac Imaging at the Giovanni XXIII Clinic, Monastier, IT
2012 UHD-Associate Professor of Radiology at EMC, Rotterdam, NL
2015 Director CT Core Lab at Montréal Heart Institute/Université de Montréal, Canada
2015 Associate Professor of Radiology at Montréal Heart Institute/Université de Montréal, Canada
Author of ~900 publications: 12 books, 86 book chapters, 347 scientific papers, >260 oral presentations, and >260 posters (h-index = 59; IF >1500).
Professor and Chair of Department of Preventive Medicine and Epidemiology at Loyola University Medical School, Chicago, IL. Preview editor of journal Ethnicity and Disease. Recipient of a 'MERIT' Award from the NIH in 2002; member of National Advisory Council and NHGRI, NIH.
PhD in cardiovascular genetics from Karolinska Institute, Sweden. Research according to an overarching theme of my research is the use of high-throughput omics to bridge the gap between research and medicine. My initial interest was in expression quantitative trait loci (eQTL), and their possibilities for translating genetics to medical use. This followed a further step into actual industrial drug and pharmacogenetics development from the technique, performed at Novo Nordisk, Denmark. Current interests focus on further translation of main genetics results into actual use both in the clinical context of response stratification and in the industrial context of drug development.
Director of the Center for Human Nutrition. Member of the American Society for Clinical Investigation, the American Association of Physicians, and the National Academies of Sciences (Institute of Medicine).
Dr. Grundy's major research area is in cholesterol and lipoprotein metabolism. He has published over 400 original papers, and numerous solicited articles and chapters. Notable research accomplishments include the development of methods for measuring cholesterol balance and biliary lipid secretion in humans, identifying the metabolic causes of cholesterol gallstones, defining effects of saturated and unsaturated fats, especially monounsaturated fatty acids, on cholesterol and lipoprotein metabolism, uncovering genetic defects underlying hypercholesterolemia and other forms of dyslipidemia, identifying metabolic defects in hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, and defining mechanisms of action of several lipid-lowering drugs, notably fibrates and HMG CoA reductase inhibitors (statins).
The overall aim of my research is to develop a mechanistic understanding of the pathogenesis of accelerated cardiac and renal dysfunction during cardio-renal syndrome. Thus, we seek to identify novel mechanisms of cardiac and renal injury in order to aid and improve diagnostic, therapeutic, and preventive strategies in this high-risk population of patients. One of the primary scientific objectives of my laboratory is to understand the pathophysiology whereby endogenous counter-regulatory mechanisms become maladaptive and contribute to disease progression in patients with cardio-renal syndrome.
Dr. Prasanna earned his BVSc (DVM) degree with honors from Bangalore Veterinary College and completed his Masters and PhD in Veterinary Pathology from Indian Veterinary Research Institute (India's premier institute for Veterinary Research). He completed his postdoctoral training at Northwestern University (in Dr. Raj Kishore's laboratory) and East Tennessee State University. Before joining University of Alabama at Birmingham (UAB), he held faculty appointments at the Feinberg Cardiovascular Research Institute, Northwestern University School of Medicine, Chicago, Illinois and Houston Methodist Research Institute, Texas.
As a member of the Department of Biomedical Engineering, he directs a research program focusing on understanding mechanisms of cardiovascular diseases and developing novel therapeutic strategies to promote cardiac regeneration and repair. Dr. Krishnamurthy’s laboratory is supported through funds from National Institutes of Health (NIH-R01) and American Heart Association (GIA and Postdoctoral fellowships).
1997: PhD Cancer Research Centre of the Russian Academy of Medical Sciences, Moscow.
1997-2001: Postdoc at the University of Regensburg
2001-2007: Junior group leader/PI and lecturer, University of Heidelberg.
2007- 2010:Senior group leader/PI and senior lecturer, University of Heidelberg
2010-2013: Professor, head of the Lab for Cellular and Molecular Biology of Innate Immunity;
2013-permanent: Professor, head of Department for Innate Immunity and Tolerance, University of Heidelberg.
Research Fellow, The University of Adelaide.
Cadiac Electrophysiologist, Royal Adelaide Hospital.
Dr Lau's PhD was focussed on the effect of hypertension on the development of atrial arrhythmias. He is recognized both nationally and internationally for his research in the area of arrhythmia substrates. To date, Dennis has co-authored more than 100 peer-reviewed publications and book chapters. His interests in atrial fibrillation include risk factor management, substrate mapping, signal analysis and mechanistic studies. He is a clinician scientist dedicated to combine preclinical studies and clinical research in the field of heart rhythm disorders.
Dr. Xing Li is an Assistant Professor and Associate Consultant in the Division of Biomedical Statistics and Informatics, Department of Health Science Research at Mayo Clinic - voted the best hospital by U.S. News & World Report. Dr. Li completed his PhD in Bioinformatics from The University of Michigan at Ann Arbor, Michigan, USA. Dr. Li also holds a Masters Degree in Biochemistry and Molecular Biology and Bachelors Degree in Microbiology. Dr. Li’s research interests focus on machine learning, bioinformatics, and statistical data mining in large scale data in biomedical research, such as next generation sequencing data (whole genome sequencing, RNA-seq, microarray data), in the file. He has published more than 20 peer-reviewed papers in reputable journals and book chapters in the fields of Bioinformatics and Biostatistics, cancer research, cardiovascular disease, embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) research, and human genomics, genetics and development, and Microbiology. Dr. Li’s publications have been highlighted as Journal Cover Stories, Journal Featured Articles, Highlights Section Papers, Must Read by Faculty 1000, and ESC & iPSC News, etc. Dr. Li has been developing data analysis tools, such as RCircle and PCA3d, etc. Dr. Li is also a member of American Association for Cancer Research (AACR), International Society for Computational Biology (ISCB), American Statistics Association (ASA) and American Heart Association (AHA).
Professor of Human Genetics, Medicine, and Microbiology,Immunology and Molecular Genetics, University of California, Los Angeles. Associate Editor, Journal of Lipid Research. Recipient of 2008 American Heart Association Duff Award and2009 NAVBO Benditt Award.